Medpace Holdings, Inc. Costs and Expenses
Medpace Holdings, Inc. (MEDP) reported Costs and Expenses of $560.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-07-23
- Medpace Holdings, Inc. costs and expenses for the quarter ending 2026-06-30 was $560.51M, a 17.51% increase year-over-year.
- Medpace Holdings, Inc. costs and expenses for the quarter ending 2026-03-31 was $565.10M, a 26.98% increase year-over-year.
- Medpace Holdings, Inc. costs and expenses for the quarter ending 2025-12-31 was $555.18M, a 35.01% increase year-over-year.
- Medpace Holdings, Inc. costs and expenses for the quarter ending 2025-09-30 was $518.10M, a 23.05% increase year-over-year.
- Medpace Holdings, Inc. costs and expenses for fiscal 2025 was $2.00B, a 20.04% increase from fiscal 2024.
- Medpace Holdings, Inc. costs and expenses for fiscal 2024 was $1.66B, a 7.31% increase from fiscal 2023.
- Medpace Holdings, Inc. costs and expenses for fiscal 2023 was $1.55B, a 31.13% increase from fiscal 2022.
- Medpace Holdings, Inc. costs and expenses for fiscal 2022 was $1.18B, a 25.17% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $560.51M 10-Q · filed 2026-07-23 | $1.13B 10-Q · filed 2026-07-23 | $1.68B derived: sum of 3 quarters · filed 2026-07-23 | $2.20B derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $565.10M 10-Q · filed 2026-04-23 | $1.12B derived: sum of 2 quarters · filed 2026-04-23 | $1.64B derived: sum of 3 quarters · filed 2026-04-23 | $2.12B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $555.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $1.07B derived: sum of 2 quarters · filed 2026-02-10 | $1.55B derived: sum of 3 quarters · filed 2026-07-23 | $2.00B 10-K · filed 2026-02-10 |
| 2025-09-30 | $518.10M 10-Q · filed 2025-10-23 | $995.07M derived: sum of 2 quarters · filed 2026-07-23 | $1.44B 10-Q · filed 2025-10-23 | $1.85B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $476.98M 10-Q · filed 2026-07-23 | $922.02M 10-Q · filed 2026-07-23 | $1.33B derived: sum of 3 quarters · filed 2026-07-23 | $1.75B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $445.05M 10-Q · filed 2026-04-23 | $856.26M derived: sum of 2 quarters · filed 2026-04-23 | $1.28B derived: sum of 3 quarters · filed 2026-04-23 | $1.70B derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $411.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $832.25M derived: sum of 2 quarters · filed 2026-02-10 | $1.26B derived: sum of 3 quarters · filed 2026-02-10 | $1.66B 10-K · filed 2026-02-10 |
| 2024-09-30 | $421.04M 10-Q · filed 2025-10-23 | $844.00M derived: sum of 2 quarters · filed 2025-10-23 | $1.25B 10-Q · filed 2025-10-23 | $1.66B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $422.95M 10-Q · filed 2025-07-22 | $829.93M 10-Q · filed 2025-07-22 | $1.24B derived: sum of 3 quarters · filed 2026-02-10 | $1.65B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $406.98M 10-Q · filed 2025-04-22 | $818.06M derived: sum of 2 quarters · filed 2026-02-10 | $1.23B derived: sum of 3 quarters · filed 2026-02-10 | $1.61B derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $411.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $818.67M derived: sum of 2 quarters · filed 2026-02-10 | $1.20B derived: sum of 3 quarters · filed 2026-02-10 | $1.55B 10-K · filed 2026-02-10 |
| 2023-09-30 | $407.59M 10-Q · filed 2024-10-22 | $790.07M derived: sum of 2 quarters · filed 2024-10-22 | $1.14B 10-Q · filed 2024-10-22 | $1.46B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $382.48M 10-Q · filed 2024-07-23 | $730.35M 10-Q · filed 2024-07-23 | $1.05B derived: sum of 3 quarters · filed 2025-02-11 | $1.35B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $347.87M 10-Q · filed 2024-04-23 | $665.54M derived: sum of 2 quarters · filed 2025-02-11 | $971.45M derived: sum of 3 quarters · filed 2025-02-11 | $1.26B derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $317.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $623.58M derived: sum of 2 quarters · filed 2025-02-11 | $914.55M derived: sum of 3 quarters · filed 2025-02-11 | $1.18B 10-K · filed 2025-02-11 |
| 2022-09-30 | $305.92M 10-Q · filed 2023-10-24 | $596.89M derived: sum of 2 quarters · filed 2023-10-24 | $863.63M 10-Q · filed 2023-10-24 | $1.12B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $290.97M 10-Q · filed 2023-07-25 | $557.72M 10-Q · filed 2023-07-25 | $811.41M derived: sum of 3 quarters · filed 2024-02-13 | $1.05B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $266.74M 10-Q · filed 2023-04-25 | $520.44M derived: sum of 2 quarters · filed 2024-02-13 | $762.29M derived: sum of 3 quarters · filed 2024-02-13 | $998.14M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $253.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $495.55M derived: sum of 2 quarters · filed 2024-02-13 | $731.40M derived: sum of 3 quarters · filed 2024-02-13 | $943.76M 10-K · filed 2024-02-13 |
| 2021-09-30 | $241.85M 10-Q · filed 2022-10-25 | $477.70M derived: sum of 2 quarters · filed 2022-10-25 | $690.07M 10-Q · filed 2022-10-25 | $894.75M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $235.84M 10-Q · filed 2022-07-26 | $448.21M 10-Q · filed 2022-07-26 | $652.90M derived: sum of 3 quarters · filed 2023-02-14 | $836.85M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $212.37M 10-Q · filed 2022-04-26 | $417.06M derived: sum of 2 quarters · filed 2023-02-14 | $601.01M derived: sum of 3 quarters · filed 2023-02-14 | $775.87M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $204.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $388.64M derived: sum of 2 quarters · filed 2023-02-14 | $563.51M derived: sum of 3 quarters · filed 2023-02-14 | $758.88M 10-K · filed 2023-02-14 |
| 2020-09-30 | $183.95M 10-Q · filed 2021-10-26 | $358.82M derived: sum of 2 quarters · filed 2021-10-26 | $554.19M 10-Q · filed 2021-10-26 | $747.96M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $174.87M 10-Q · filed 2021-07-27 | $370.24M 10-Q · filed 2021-07-27 | $564.01M derived: sum of 3 quarters · filed 2022-02-15 | $750.26M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $195.38M 10-Q · filed 2021-04-27 | $389.14M derived: sum of 2 quarters · filed 2022-02-15 | $575.39M derived: sum of 3 quarters · filed 2022-02-15 | $754.24M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $193.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $380.01M derived: sum of 2 quarters · filed 2022-02-15 | $558.86M derived: sum of 3 quarters · filed 2022-02-15 | $733.71M 10-K · filed 2022-02-15 |
| 2019-09-30 | $186.25M 10-Q · filed 2020-10-27 | $365.09M derived: sum of 2 quarters · filed 2020-10-27 | $539.94M 10-Q · filed 2020-10-27 | $701.39M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $178.84M 10-Q · filed 2020-07-28 | $353.69M 10-Q · filed 2020-07-28 | $515.14M derived: sum of 3 quarters · filed 2021-02-16 | $667.48M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $174.85M 10-Q · filed 2020-04-29 | $336.30M derived: sum of 2 quarters · filed 2021-02-16 | $488.63M derived: sum of 3 quarters · filed 2021-02-16 | $635.43M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | $161.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $313.78M derived: sum of 2 quarters · filed 2021-02-16 | $460.58M derived: sum of 3 quarters · filed 2021-02-16 | $603.54M 10-K · filed 2021-02-16 |
| 2018-09-30 | $152.34M 10-Q · filed 2019-10-29 | $299.13M derived: sum of 2 quarters · filed 2019-10-29 | $442.09M 10-Q · filed 2019-10-29 | $539.34M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $146.80M 10-Q · filed 2019-07-30 | $289.76M 10-Q · filed 2019-07-30 | $387.00M derived: sum of 3 quarters · filed 2020-02-25 | $480.45M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $142.96M 10-Q · filed 2019-04-30 | $240.20M derived: sum of 2 quarters · filed 2020-02-25 | $333.65M derived: sum of 3 quarters · filed 2020-02-25 | $423.58M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $97.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $190.69M derived: sum of 2 quarters · filed 2020-02-25 | $280.63M derived: sum of 3 quarters · filed 2020-02-25 | $371.29M 10-K · filed 2020-02-25 |
| 2017-09-30 | $93.44M 10-Q · filed 2018-10-30 | $183.38M derived: sum of 2 quarters · filed 2018-10-30 | $274.05M 10-Q · filed 2018-10-30 | $369.40M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $89.94M 10-Q · filed 2018-07-31 | $180.60M 10-Q · filed 2018-07-31 | $275.96M derived: sum of 3 quarters · filed 2019-02-26 | $371.14M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $90.67M 10-Q · filed 2018-05-01 | $186.02M derived: sum of 2 quarters · filed 2019-02-26 | $281.20M derived: sum of 3 quarters · filed 2019-02-26 | $373.04M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $95.35M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $190.53M derived: sum of 2 quarters · filed 2019-02-26 | $282.38M derived: sum of 3 quarters · filed 2019-02-26 | $369.09M 10-K · filed 2019-02-26 |
| 2016-09-30 | $95.18M 10-Q · filed 2017-10-31 | $187.02M derived: sum of 2 quarters · filed 2017-10-31 | $273.74M 10-Q · filed 2017-10-31 | $370.67M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $91.84M 10-Q · filed 2017-08-01 | $178.56M 10-Q · filed 2017-08-01 | $275.49M derived: sum of 3 quarters · filed 2018-02-27 | $360.42M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $86.72M 10-Q · filed 2017-05-02 | $183.65M derived: sum of 2 quarters · filed 2018-02-27 | $268.58M derived: sum of 3 quarters · filed 2018-02-27 | |
| 2015-12-31 | $96.93M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $181.87M derived: sum of 2 quarters · filed 2018-02-27 | $338.50M 10-K · filed 2018-02-27 | |
| 2015-09-30 | $84.94M 10-Q · filed 2016-11-03 | $241.57M 10-Q · filed 2016-11-03 | ||
| 2014-12-31 | $246.05M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |